EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone
Grade 3 to 4 rash · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 rash compared with chemotherapy alone (very low certainty).
1 finding from 1 review
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes onlyRR 13.63 [0.78, 236.87]1 study · 125 participantsVery low